TG Therapeutics Inc (STU:NKB2)
€ 16.184 0.574 (3.68%) Market Cap: 2.54 Bil Enterprise Value: 2.45 Bil PE Ratio: 80.14 PB Ratio: 17.02 GF Score: 73/100

TG Therapeutics Inc to Discuss Phase 1 U2 + Venetoclax Data Call Transcript

Sep 20, 2021 / 12:30PM GMT
Release Date Price: €25.79 (-0.50%)
Operator

Hello and welcome to the TG Therapeutics iwCLL Investor and Analyst Virtual Event. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Jenna Bosco. You may begin.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Good morning, and thank you all for joining us. My name is Jenna Bosco, and I'm the Head of Corporate Communications for TG Therapeutics. And I welcome you all to our virtual event this morning.

Before we begin, I just wanted to remind everyone that we anticipate making some forward-looking statements based on our current expectations. These statements involve risks and uncertainties that can cause our actual results to differ materially from those indicated. For a description of these risks, we encourage you to review the disclosures on this slide and also in our latest reports filed with the SEC, which are available on our corporate website at www

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot